Serum analyses in patients afflicted with RA have revealed elevated levels of the activation fragment of F2RL1, which, crucially, exhibit a decrement in response to anti-IL6 receptor (IL6R) treatment. This evidence concerns the gene F2RL1 and rheumatoid arthritis.